OCA
JNCE

Octagon Capital Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Octagon Capital Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,400,000
Closed -$1.55M – 46
2022
Q4 		$1.55M Hold
1,400,000
– – 0.24% 29
2022
Q3 		$3.28M Buy
+1,400,000
New +$4.96M 0.57% 25

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Octagon Capital Advisors's JNCE Position: Q1 2023 in Review

Octagon Capital Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 1,400,000 shares — an estimated $1.55M sold.

Octagon Capital Advisors first reported a position in JNCE in Q3 2022 and held it in 2 quarters. The position peaked at $3.28M in Q3 2022. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Octagon Capital Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,400,000 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.55M.
  • Octagon Capital Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Octagon Capital Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $3.28M in Q3 2022.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Octagon Capital Advisors's 13F filing for Q1 2023, filed 15 May 2023.